<?xml version="1.0" encoding="UTF-8"?>
<p>Obesity is also associated with chronic low-grade inflammation, dysbiosis, and increased secretion of inflammatory cytokines, including interleukin 6 (IL-6) (
 <xref rid="B20" ref-type="bibr">20</xref>). Elevated plasma levels of pro-inflammatory cytokines are observed in COVID-19 infected patients; in particular, IL-6 and ferritin release have been identified as predictors of fatality (
 <xref rid="B21" ref-type="bibr">21</xref>). Several studies focusing on previous outbreaks of severe influenza confirmed that the mortality caused by organ injury could be reduced by immunomodulatory agents (
 <xref rid="B22" ref-type="bibr">22</xref>, 
 <xref rid="B23" ref-type="bibr">23</xref>). Currently, a study on the safety and efficacy of Tocilizumab is being conducted (ClinicalTrials.gov Identifier: NCT04317092) (
 <xref rid="B24" ref-type="bibr">24</xref>) to assess its capacity to suppress the virally driven hyperinflammation and acute respiratory syndrome caused by COVID-19.
</p>
